✦ LIBER ✦

Omapatrilat in patients with hepatic cirrhosis

✍ Scribed by P. O'Grady; O. Vesterqvist; B. Malhotra; J. Manning; M. Jemal; G. Ge; B. Mangold

Publisher: Springer
Year: 2001
Tongue: English
Weight: 211 KB
Volume: 57
Category: Article
ISSN: 0031-6970
DOI: 10.1007/s002280100291

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Omapatrilat in patients with hepatic cir

Omapatrilat in patients with hepatic cirrhosis

✍ P. O'Grady; O. Vesterqvist; B. Malhotra; J. Manning; M. Jemal; G. Ge; B. Mangold 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 211 KB

Pharmacokinetics of furosemide in patien

Pharmacokinetics of furosemide in patients with hepatic cirrhosis

✍ G. González; A. Arancibia; M. I. Rivas; P. Caro; C. Antezana 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 610 KB

Cardiovascular effects of octreotide in

Cardiovascular effects of octreotide in patients with hepatic cirrhosis

✍ P. Aiden McCormick; Jason Chin; Lynda Greenslade; Stelios Karatapanis; Robert Di 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 679 KB

Octreotide is thought to reduce splanchnic and variceal blood flow with minimal effects on the systemic circulation in cirrhotic patients with portal hypertension. However, we noticed significant bradycardia in some patients immediately after administration of bolus doses of octreotide. Therefore, w

Gram-negative bacillary cellulitis in pa

Gram-negative bacillary cellulitis in patients with hepatic cirrhosis

✍ J. M. Corredoira; J. Ariza; R. Pallarés; J. Carratalá; P. F. Viladrich; G. Rufí; 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 933 KB

Kinetics of intravenous metoclopramide i

Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis

✍ F. Albani; M. R. Tamè; R. Palma; M. Bernardi 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 276 KB

The pharmacokinetics of metoclopramide has been studied after acute IV administration to 12 patients with hepatic cirrhosis (6 with and 6 without ascites) and 6 control subjects. The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respe

Therapy of hepatitis C: Patients with ci

Therapy of hepatitis C: Patients with cirrhosis

✍ S W Schalm; G Fattovich; J T Brouwer 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

The management of both compensated and decompensated progressed to cirrhosis is estimated to be 20% to 30%. 1 In addition to patients who present with symptoms or signs cirrhosis caused by hepatitis C must be viewed in the context of the natural history of the disease. The prognosis of compen-of chr